HepaHope, Inc.
HepaHope, Inc. to list its shares in the Prime Standard of the Frankfurt Stock Exchange
HepaHope, Inc. / Regulatory Admission Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. HepaHope, Inc. to list its shares in the Prime Standard of the Frankfurt Stock Exchange -Admission expected in 2009 Irvine (California, USA), June 18, 2009 - HepaHope, Inc. (Symbol: 0HH1) today announced that it is applying to have its shares admitted for trading on the Regulated Market of the Frankfurt Stock Exchange with concurrent admission in the Prime Standard. The Company's shares currently are included in the Entry Standard (Open Market) of the Frankfurt Stock Exchange. The Prime Standard offers investors the highest transparency standards available in Europe. As the Company continues to grow and prepare for its upcoming Phase I clinical trials, it hopes the greater transparency and additional information requirements of the Prime Standard will foster a broader understanding of its operations among the investment community. HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products for patients with chronic and acute liver disease. Disclaimer No stock exchange or regulatory authority has approved or disapproved of the information contained herein. The securities offered were not registered under the United States Securities Act of 1933 (the '1933 Act') or the securities laws of any state and may not be offered or sold in the United States or to U.S. persons, except pursuant to registration under the 1933 Act or pursuant to an available exemption from such registration requirements. In particular, the securities are subject to a 'distribution compliance period' of at least one year during which they may not be offered or sold to persons in the United States or U.S. persons except in transactions exempt from registration under the 1933 Act. About HepaHope: HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure. The Company's leading proprietary technology, the HepaPheresis(TM) System, is based on an Organ Slice Cultivation Technology which aims to maintain the functionality of various organs out of the body (ex vivo) in order to better support liver failure patients. The HepaPheresis(TM) System is currently being prepared for Phase I clinical trials. HepaHope's patented core technology for organ slice cultivation is also the foundation of other product candidates in the pipeline of this company in the oncology testing market and the drug development market. The members of the management and science advisory board of the company represent leading scientists in liver research. HepaHope was founded in February 1999. The offices and research facilities of the US Company are both located in California. For further information please visit: www.hepahope.com HepaHope, Inc. Bhavesh Singh Chief Financial Officer P + 1 949 421 3617 M + 1 201 920 1819 Investor Relations IR.on AG Achim Josten Dariusch Manssuri T +49 221. 9140.970 F +49 221. 9140.978 E-mail: info@ir-on.com 18.06.2009 Financial News transmitted by DGAP ---------------------------------------------------------------------- Language: English Issuer: HepaHope, Inc. 30 Fairbanks, Suite 110 CA 92618 Irvin Vereinigte Staaten von Amerika Phone: 001 9494213600 Fax: 001 9494213680 E-mail: investor@hepahope.com Internet: http://www.hepahope.com ISIN: US42689N1090, USU425541021 WKN: A0RMY4, A0RLC1 Listed: Freiverkehr in Düsseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of News DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found